Immunovia Publ Ab Stock Current Valuation
| IMMNOV Stock | SEK 0.33 0.01 2.94% |
Valuation analysis of Immunovia publ AB helps investors to measure Immunovia Publ's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Immunovia Publ's price fluctuation is out of control at this time. Calculation of the real value of Immunovia publ AB is based on 3 months time horizon. Increasing Immunovia Publ's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Immunovia Publ is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunovia Stock. However, Immunovia Publ's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.33 | Real 0.32 | Hype 0.33 |
The real value of Immunovia Stock, also known as its intrinsic value, is the underlying worth of Immunovia publ AB Company, which is reflected in its stock price. It is based on Immunovia Publ's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Immunovia Publ's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Immunovia publ AB helps investors to forecast how Immunovia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunovia Publ more accurately as focusing exclusively on Immunovia Publ's fundamentals will not take into account other important factors: Immunovia publ AB Company Current Valuation Analysis
Immunovia Publ's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immunovia Publ Current Valuation | 536.89 M |
Most of Immunovia Publ's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunovia publ AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Immunovia publ AB has a Current Valuation of 536.89 M. This is 96.26% lower than that of the Healthcare sector and 93.11% lower than that of the Diagnostics & Research industry. The current valuation for all Sweden stocks is 96.77% higher than that of the company.
Immunovia Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunovia Publ's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunovia Publ could also be used in its relative valuation, which is a method of valuing Immunovia Publ by comparing valuation metrics of similar companies.Immunovia Publ is currently under evaluation in current valuation category among its peers.
Immunovia Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (201.30) % | |||
| Current Valuation | 536.89 M | |||
| Shares Outstanding | 22.63 M | |||
| Shares Owned By Insiders | 36.15 % | |||
| Shares Owned By Institutions | 4.60 % | |||
| Price To Earning | (57.93) X | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 683.47 X | |||
| Revenue | 844 K | |||
| Gross Profit | 15.81 M | |||
| EBITDA | (135.47 M) | |||
| Net Income | (166.63 M) | |||
| Cash And Equivalents | 359.85 M | |||
| Cash Per Share | 18.42 X | |||
| Total Debt | 27.16 M | |||
| Debt To Equity | 7.80 % | |||
| Current Ratio | 14.26 X | |||
| Book Value Per Share | 13.09 X | |||
| Cash Flow From Operations | (152.65 M) | |||
| Earnings Per Share | (7.80) X | |||
| Target Price | 110.0 | |||
| Number Of Employees | 64 | |||
| Beta | 1.29 | |||
| Market Capitalization | 479.62 M | |||
| Total Asset | 493.81 M | |||
| Z Score | 10.2 | |||
| Net Asset | 493.81 M |
About Immunovia Publ Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunovia publ AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovia Publ using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovia publ AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Immunovia Stock
Immunovia Publ financial ratios help investors to determine whether Immunovia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immunovia with respect to the benefits of owning Immunovia Publ security.